| 17.34 Data as of Jun 18 |  +0.10 / +0.58%Today’s Change | 13.87 Today|||52-Week Range 29.37 | -6.47% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $855.0M |
Company Description
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company. It focuses on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons. The company currently markets two products in the United States: Testim testosterone gel and XIAFLEX. The Testim testosterone gel is a proprietary, topical testosterone once-a-day gel indicated for the treatment of hypogonadism. The XIAFLEX is a proprietary, injectable collagenase enzyme approved by the United States Food and Drug Administration for the treatment of Dupuytren's contracture in adult patients with a palpable cord. Auxilium Pharmaceuticals was founded by Gerri A. Henwood and Jane Holmes Hollingsworth in 1999 and is headquartered in Chesterbrook, PA.
Employees
Shareholders
| Other institutional | 60.95% |
| Mutual fund holders | 38.76% |
| Individual stakeholders | 29.73% |
Top Executives
| Adrian Adams | President, Chief Executive Officer & Director |
| James E. Fickenscher, CPA | Chief Financial Officer & Head-Investor Relations |
| James Patrick Tursi, MD | Chief Medical Officer |
| Andrew I. Koven | Secretary, Executive VP & General Counsel |
| Alan J. Wills, MBA | Executive Vice President-Corporate Development |
.
